GILD boasts a market-leading portfolio of HIV treatments both for treating the disease and prevention. The company has two drugs for HIV prevention in its portfolio, Descovy and Truvada.
Why: The stock's decline follows a report from The Wall Street Journal that the US Health and Human Services Department is considering drastic cuts to federal funding for HIV prevention in the US.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback